Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pituitary ACTH Hypersecretion | 41 | 2025 | 180 | 12.220 |
Why?
|
Human Growth Hormone | 69 | 2024 | 651 | 10.670 |
Why?
|
Cushing Syndrome | 35 | 2024 | 241 | 7.390 |
Why?
|
Acromegaly | 24 | 2024 | 317 | 4.430 |
Why?
|
Somatostatin | 20 | 2024 | 458 | 4.170 |
Why?
|
Hormone Replacement Therapy | 20 | 2021 | 757 | 3.080 |
Why?
|
Hydrocortisone | 42 | 2025 | 1841 | 2.960 |
Why?
|
Hypopituitarism | 17 | 2019 | 253 | 2.880 |
Why?
|
Dwarfism, Pituitary | 9 | 2022 | 39 | 2.500 |
Why?
|
Pituitary Neoplasms | 31 | 2023 | 1322 | 1.750 |
Why?
|
Adenoma | 21 | 2022 | 2159 | 1.670 |
Why?
|
Growth Hormone | 20 | 2022 | 573 | 1.610 |
Why?
|
Insulin-Like Growth Factor I | 36 | 2024 | 1942 | 1.590 |
Why?
|
Receptors, Somatotropin | 5 | 2020 | 58 | 1.580 |
Why?
|
Ketoconazole | 6 | 2021 | 95 | 1.430 |
Why?
|
Adrenocorticotropic Hormone | 20 | 2019 | 619 | 1.410 |
Why?
|
ACTH-Secreting Pituitary Adenoma | 5 | 2020 | 64 | 1.410 |
Why?
|
Dopamine Agonists | 10 | 2023 | 347 | 1.400 |
Why?
|
Adrenal Insufficiency | 10 | 2022 | 195 | 1.340 |
Why?
|
Hyperprolactinemia | 10 | 2023 | 124 | 1.300 |
Why?
|
Hormones | 7 | 2020 | 866 | 1.230 |
Why?
|
Octreotide | 6 | 2024 | 156 | 1.080 |
Why?
|
Pituitary Gland | 7 | 2021 | 634 | 1.070 |
Why?
|
Glucagon | 6 | 2016 | 535 | 1.020 |
Why?
|
Mifepristone | 6 | 2020 | 151 | 0.980 |
Why?
|
Receptors, Glucocorticoid | 3 | 2018 | 309 | 0.970 |
Why?
|
Endocrinology | 6 | 2020 | 443 | 0.940 |
Why?
|
Receptors, Somatostatin | 2 | 2024 | 138 | 0.930 |
Why?
|
Imidazoles | 9 | 2025 | 1169 | 0.910 |
Why?
|
Diagnostic Techniques, Endocrine | 3 | 2012 | 43 | 0.880 |
Why?
|
Hormone Antagonists | 6 | 2017 | 108 | 0.880 |
Why?
|
Quality of Life | 21 | 2024 | 13490 | 0.750 |
Why?
|
Bone Density | 14 | 2017 | 3573 | 0.730 |
Why?
|
Body Composition | 17 | 2020 | 2462 | 0.680 |
Why?
|
Arginine | 7 | 2020 | 932 | 0.640 |
Why?
|
Petrosal Sinus Sampling | 3 | 2012 | 22 | 0.640 |
Why?
|
Adult | 135 | 2025 | 223646 | 0.620 |
Why?
|
Pituitary-Adrenal System | 5 | 2016 | 555 | 0.610 |
Why?
|
Pyridines | 8 | 2025 | 2894 | 0.580 |
Why?
|
Antimetabolites | 1 | 2018 | 128 | 0.580 |
Why?
|
Hypothalamo-Hypophyseal System | 5 | 2016 | 702 | 0.580 |
Why?
|
Circadian Rhythm | 5 | 2020 | 2593 | 0.570 |
Why?
|
Corticotropin-Releasing Hormone | 7 | 2012 | 361 | 0.550 |
Why?
|
Prolactinoma | 5 | 2023 | 114 | 0.550 |
Why?
|
Recombinant Proteins | 8 | 2020 | 6514 | 0.540 |
Why?
|
Treatment Outcome | 38 | 2024 | 65371 | 0.540 |
Why?
|
Mitotane | 4 | 2020 | 20 | 0.520 |
Why?
|
Cranial Irradiation | 2 | 2017 | 393 | 0.510 |
Why?
|
Metyrapone | 4 | 2019 | 22 | 0.490 |
Why?
|
Humans | 188 | 2025 | 768166 | 0.480 |
Why?
|
Middle Aged | 100 | 2025 | 223492 | 0.470 |
Why?
|
Steroid 11-beta-Hydroxylase | 1 | 2013 | 20 | 0.450 |
Why?
|
Female | 123 | 2025 | 397192 | 0.450 |
Why?
|
Saliva | 7 | 2020 | 853 | 0.450 |
Why?
|
Neurotransmitter Agents | 1 | 2018 | 663 | 0.450 |
Why?
|
Radiosurgery | 6 | 2017 | 1330 | 0.440 |
Why?
|
Ergolines | 5 | 2017 | 56 | 0.430 |
Why?
|
Male | 104 | 2025 | 364719 | 0.400 |
Why?
|
Growth Disorders | 5 | 2019 | 635 | 0.400 |
Why?
|
Enzyme Inhibitors | 4 | 2022 | 3728 | 0.390 |
Why?
|
Prolactin | 8 | 2023 | 627 | 0.380 |
Why?
|
ACTH Syndrome, Ectopic | 2 | 2008 | 30 | 0.370 |
Why?
|
Heart Valves | 2 | 2010 | 284 | 0.370 |
Why?
|
Young Adult | 36 | 2024 | 60066 | 0.360 |
Why?
|
Adrenalectomy | 5 | 2017 | 348 | 0.360 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2018 | 1536 | 0.350 |
Why?
|
Double-Blind Method | 17 | 2024 | 12465 | 0.350 |
Why?
|
Consensus | 7 | 2021 | 3212 | 0.340 |
Why?
|
Databases, Factual | 9 | 2015 | 8080 | 0.330 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2020 | 10760 | 0.320 |
Why?
|
Amenorrhea | 7 | 1999 | 484 | 0.310 |
Why?
|
Societies, Scientific | 1 | 2009 | 223 | 0.310 |
Why?
|
Aged | 50 | 2024 | 171504 | 0.280 |
Why?
|
Gonadal Steroid Hormones | 1 | 2011 | 707 | 0.270 |
Why?
|
Delayed-Action Preparations | 8 | 2018 | 969 | 0.270 |
Why?
|
Blood Glucose | 12 | 2025 | 6430 | 0.260 |
Why?
|
Drug Administration Schedule | 8 | 2018 | 4860 | 0.260 |
Why?
|
Metabolism, Inborn Errors | 2 | 2007 | 292 | 0.260 |
Why?
|
Pituitary Diseases | 5 | 2016 | 137 | 0.260 |
Why?
|
Lumbar Vertebrae | 2 | 2013 | 1885 | 0.250 |
Why?
|
Craniopharyngioma | 3 | 2017 | 279 | 0.240 |
Why?
|
Pituitary Hormones, Anterior | 2 | 2022 | 57 | 0.220 |
Why?
|
Dexamethasone | 4 | 2009 | 1965 | 0.220 |
Why?
|
Remission Induction | 6 | 2015 | 2410 | 0.220 |
Why?
|
Tryptophan | 2 | 2018 | 482 | 0.220 |
Why?
|
Etomidate | 2 | 2019 | 185 | 0.220 |
Why?
|
Neurosurgical Procedures | 4 | 2020 | 2076 | 0.220 |
Why?
|
Administration, Oral | 5 | 2024 | 4030 | 0.220 |
Why?
|
Retrospective Studies | 30 | 2021 | 81762 | 0.210 |
Why?
|
Insulin | 8 | 2022 | 6607 | 0.210 |
Why?
|
Growth Hormone-Releasing Hormone | 4 | 2013 | 128 | 0.210 |
Why?
|
Bone Diseases, Metabolic | 5 | 1995 | 411 | 0.210 |
Why?
|
Reference Values | 7 | 2016 | 4938 | 0.210 |
Why?
|
Peptides, Cyclic | 1 | 2024 | 391 | 0.200 |
Why?
|
Adipose Tissue | 5 | 2011 | 3329 | 0.200 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 747 | 0.200 |
Why?
|
Heart Valve Diseases | 1 | 2010 | 1030 | 0.200 |
Why?
|
Adolescent | 36 | 2023 | 89169 | 0.200 |
Why?
|
Hyperlipidemias | 2 | 2017 | 772 | 0.190 |
Why?
|
Age of Onset | 6 | 2018 | 3347 | 0.190 |
Why?
|
Leydig Cell Tumor | 1 | 2001 | 28 | 0.190 |
Why?
|
Mixed Function Oxygenases | 1 | 2022 | 265 | 0.190 |
Why?
|
Bone and Bones | 5 | 2009 | 2589 | 0.180 |
Why?
|
Hypertension | 6 | 2025 | 8616 | 0.180 |
Why?
|
Follow-Up Studies | 12 | 2020 | 39348 | 0.180 |
Why?
|
Cosyntropin | 2 | 2021 | 34 | 0.180 |
Why?
|
Absorptiometry, Photon | 7 | 2017 | 1758 | 0.180 |
Why?
|
Gynecomastia | 1 | 2001 | 88 | 0.180 |
Why?
|
Prospective Studies | 12 | 2024 | 54926 | 0.180 |
Why?
|
Body Mass Index | 10 | 2019 | 13053 | 0.170 |
Why?
|
Body Height | 4 | 2018 | 1565 | 0.170 |
Why?
|
Internationality | 2 | 2018 | 1008 | 0.170 |
Why?
|
Testosterone | 6 | 2022 | 2491 | 0.170 |
Why?
|
Insulin Resistance | 3 | 2012 | 3986 | 0.160 |
Why?
|
Glucocorticoids | 2 | 2020 | 2167 | 0.160 |
Why?
|
Hypoglycemic Agents | 4 | 2017 | 3109 | 0.160 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2021 | 260 | 0.160 |
Why?
|
Postoperative Care | 2 | 2005 | 1480 | 0.160 |
Why?
|
Pituitary Function Tests | 1 | 2018 | 24 | 0.160 |
Why?
|
Practice Guidelines as Topic | 5 | 2021 | 7454 | 0.160 |
Why?
|
Blood Pressure | 4 | 2025 | 8543 | 0.150 |
Why?
|
Central Nervous System Cysts | 2 | 2016 | 56 | 0.150 |
Why?
|
Nelson Syndrome | 2 | 2008 | 20 | 0.150 |
Why?
|
Technology, Pharmaceutical | 1 | 2018 | 84 | 0.150 |
Why?
|
Waist Circumference | 2 | 2019 | 935 | 0.150 |
Why?
|
14-alpha Demethylase Inhibitors | 1 | 2017 | 4 | 0.150 |
Why?
|
Pituitary Irradiation | 1 | 2017 | 14 | 0.150 |
Why?
|
Medical Oncology | 1 | 2009 | 2346 | 0.150 |
Why?
|
Striae Distensae | 1 | 2017 | 7 | 0.150 |
Why?
|
Ligands | 1 | 2024 | 3284 | 0.150 |
Why?
|
Indoles | 2 | 2018 | 1836 | 0.140 |
Why?
|
Hypothalamic Diseases | 4 | 2012 | 134 | 0.140 |
Why?
|
Pregnancy Outcome | 2 | 2021 | 2972 | 0.140 |
Why?
|
Stimulation, Chemical | 2 | 2011 | 305 | 0.140 |
Why?
|
Hirsutism | 1 | 2017 | 68 | 0.140 |
Why?
|
Europe | 3 | 2019 | 3436 | 0.140 |
Why?
|
Sensitivity and Specificity | 7 | 2018 | 14729 | 0.140 |
Why?
|
Diagnostic Errors | 1 | 2004 | 1281 | 0.140 |
Why?
|
Alanine Transaminase | 1 | 2019 | 606 | 0.140 |
Why?
|
Child | 19 | 2023 | 80917 | 0.130 |
Why?
|
Age Factors | 7 | 2020 | 18412 | 0.130 |
Why?
|
Body Weight | 5 | 2016 | 4627 | 0.130 |
Why?
|
Adrenal Hyperplasia, Congenital | 1 | 2016 | 98 | 0.130 |
Why?
|
Hypothalamus | 2 | 1991 | 1004 | 0.120 |
Why?
|
Injections | 1 | 2018 | 840 | 0.120 |
Why?
|
Electric Impedance | 1 | 2019 | 794 | 0.120 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2000 | 628 | 0.120 |
Why?
|
Testicular Neoplasms | 1 | 2001 | 806 | 0.120 |
Why?
|
Radius | 2 | 2017 | 443 | 0.120 |
Why?
|
Sex Characteristics | 5 | 2011 | 2650 | 0.120 |
Why?
|
Long QT Syndrome | 1 | 2019 | 472 | 0.120 |
Why?
|
Cardiovascular Diseases | 11 | 2020 | 15662 | 0.120 |
Why?
|
Pituitary Apoplexy | 1 | 2014 | 29 | 0.120 |
Why?
|
Cholesterol | 3 | 2014 | 2914 | 0.120 |
Why?
|
Muscular Atrophy | 1 | 2017 | 335 | 0.110 |
Why?
|
Muscle Weakness | 1 | 2017 | 412 | 0.110 |
Why?
|
Thiazolidinediones | 1 | 2017 | 461 | 0.110 |
Why?
|
Obesity, Abdominal | 1 | 2017 | 375 | 0.110 |
Why?
|
Thyrotropin | 3 | 2014 | 834 | 0.110 |
Why?
|
Time Factors | 13 | 2020 | 40218 | 0.110 |
Why?
|
Radiotherapy | 1 | 2020 | 1502 | 0.110 |
Why?
|
Androgens | 3 | 2007 | 1281 | 0.110 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2017 | 383 | 0.100 |
Why?
|
Glucose Tolerance Test | 2 | 2017 | 1183 | 0.100 |
Why?
|
Hospitals, General | 1 | 1997 | 809 | 0.100 |
Why?
|
United States | 8 | 2022 | 73039 | 0.100 |
Why?
|
Diagnostic Tests, Routine | 1 | 2018 | 789 | 0.100 |
Why?
|
Patient Care Team | 2 | 2021 | 2523 | 0.100 |
Why?
|
Tetrahydronaphthalenes | 1 | 2012 | 85 | 0.100 |
Why?
|
Urinalysis | 1 | 2013 | 370 | 0.090 |
Why?
|
Sex Factors | 4 | 2013 | 10632 | 0.090 |
Why?
|
Impulsive Behavior | 1 | 2014 | 345 | 0.090 |
Why?
|
Femur Neck | 1 | 2013 | 318 | 0.090 |
Why?
|
Ghrelin | 1 | 2013 | 251 | 0.090 |
Why?
|
Tumor Burden | 1 | 2017 | 1906 | 0.090 |
Why?
|
Ambulatory Care Facilities | 1 | 1997 | 939 | 0.090 |
Why?
|
Cysts | 1 | 2016 | 685 | 0.090 |
Why?
|
Case-Control Studies | 5 | 2020 | 22291 | 0.090 |
Why?
|
Sella Turcica | 1 | 2010 | 117 | 0.090 |
Why?
|
Meningioma | 2 | 2017 | 1220 | 0.090 |
Why?
|
Comorbidity | 4 | 2020 | 10590 | 0.090 |
Why?
|
Pregnancy | 6 | 2023 | 30256 | 0.090 |
Why?
|
Cross-Sectional Studies | 8 | 2018 | 26379 | 0.090 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2015 | 735 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 1791 | 0.080 |
Why?
|
Adipokines | 1 | 2011 | 309 | 0.080 |
Why?
|
Neurology | 1 | 1997 | 786 | 0.080 |
Why?
|
Perception | 1 | 2015 | 1209 | 0.080 |
Why?
|
Child Welfare | 1 | 2013 | 523 | 0.080 |
Why?
|
Insurance Coverage | 1 | 2000 | 1946 | 0.080 |
Why?
|
Diagnosis, Differential | 6 | 2010 | 13014 | 0.080 |
Why?
|
Neuroblastoma | 1 | 2017 | 1266 | 0.080 |
Why?
|
Pharmacoepidemiology | 1 | 2012 | 351 | 0.080 |
Why?
|
Mortality | 1 | 2020 | 2911 | 0.080 |
Why?
|
Nose | 1 | 2012 | 522 | 0.080 |
Why?
|
Needs Assessment | 1 | 2014 | 1141 | 0.080 |
Why?
|
Hypophysectomy | 1 | 2008 | 114 | 0.080 |
Why?
|
Knowledge | 1 | 2009 | 178 | 0.080 |
Why?
|
Prognosis | 5 | 2020 | 30010 | 0.070 |
Why?
|
Early Diagnosis | 1 | 2013 | 1194 | 0.070 |
Why?
|
Estrogens | 4 | 2022 | 1536 | 0.070 |
Why?
|
Statistics, Nonparametric | 2 | 2012 | 2862 | 0.070 |
Why?
|
ROC Curve | 3 | 2020 | 3628 | 0.070 |
Why?
|
Meningeal Neoplasms | 1 | 2017 | 1253 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6316 | 0.070 |
Why?
|
Professional Practice | 1 | 2009 | 314 | 0.070 |
Why?
|
Endocrine System Diseases | 2 | 2002 | 250 | 0.070 |
Why?
|
Aged, 80 and over | 12 | 2018 | 59629 | 0.070 |
Why?
|
Cross-Over Studies | 4 | 2018 | 2107 | 0.070 |
Why?
|
Bromocriptine | 3 | 2007 | 93 | 0.070 |
Why?
|
Single-Blind Method | 4 | 2012 | 1587 | 0.070 |
Why?
|
Anorexia Nervosa | 3 | 1995 | 1364 | 0.070 |
Why?
|
Steroid Metabolism, Inborn Errors | 1 | 2005 | 5 | 0.060 |
Why?
|
Recurrence | 7 | 2015 | 8509 | 0.060 |
Why?
|
Bariatric Surgery | 1 | 2015 | 1001 | 0.060 |
Why?
|
Spine | 3 | 2011 | 1140 | 0.060 |
Why?
|
Homeostasis | 1 | 2016 | 3348 | 0.060 |
Why?
|
Quinazolines | 1 | 2012 | 1373 | 0.060 |
Why?
|
Triglycerides | 1 | 2013 | 2464 | 0.060 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 3837 | 0.060 |
Why?
|
Injections, Subcutaneous | 2 | 2022 | 687 | 0.060 |
Why?
|
Drug Interactions | 1 | 2009 | 1419 | 0.060 |
Why?
|
Differential Threshold | 1 | 2004 | 80 | 0.060 |
Why?
|
Obesity, Morbid | 1 | 2015 | 1298 | 0.060 |
Why?
|
Levodopa | 2 | 2002 | 221 | 0.060 |
Why?
|
Deficiency Diseases | 1 | 2004 | 74 | 0.060 |
Why?
|
Estradiol | 3 | 2001 | 1951 | 0.060 |
Why?
|
Analysis of Variance | 2 | 2011 | 6229 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2010 | 14783 | 0.060 |
Why?
|
Risk Factors | 12 | 2020 | 74944 | 0.060 |
Why?
|
Pituitary Hormones | 2 | 2021 | 182 | 0.060 |
Why?
|
Overweight | 1 | 2014 | 2448 | 0.050 |
Why?
|
Societies, Medical | 1 | 2015 | 3968 | 0.050 |
Why?
|
False Negative Reactions | 1 | 2004 | 574 | 0.050 |
Why?
|
International Cooperation | 1 | 2009 | 1436 | 0.050 |
Why?
|
Oligopeptides | 1 | 2008 | 1194 | 0.050 |
Why?
|
Intra-Abdominal Fat | 1 | 2008 | 625 | 0.050 |
Why?
|
Chemistry, Pharmaceutical | 2 | 2015 | 273 | 0.050 |
Why?
|
Osteoporosis | 2 | 2009 | 1605 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2013 | 5315 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
Phenol | 1 | 2022 | 45 | 0.050 |
Why?
|
Models, Theoretical | 1 | 2014 | 3573 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2022 | 9419 | 0.050 |
Why?
|
Radiography | 1 | 2013 | 6983 | 0.050 |
Why?
|
Logistic Models | 1 | 2016 | 13290 | 0.050 |
Why?
|
Glioma | 1 | 2017 | 3503 | 0.050 |
Why?
|
Mannitol | 1 | 2022 | 176 | 0.050 |
Why?
|
Homocystine | 1 | 2001 | 21 | 0.050 |
Why?
|
Histidine | 1 | 2022 | 301 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2020 | 6526 | 0.050 |
Why?
|
Anxiety | 1 | 2016 | 4672 | 0.050 |
Why?
|
Diabetes Mellitus | 2 | 2016 | 5889 | 0.050 |
Why?
|
Hepatitis C Antibodies | 1 | 2001 | 151 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2019 | 20227 | 0.050 |
Why?
|
Child, Preschool | 5 | 2018 | 42669 | 0.050 |
Why?
|
Hospitalization | 2 | 2021 | 10840 | 0.050 |
Why?
|
Postoperative Period | 2 | 2015 | 1826 | 0.040 |
Why?
|
Heroin Dependence | 1 | 2001 | 173 | 0.040 |
Why?
|
Sphenoid Bone | 2 | 2014 | 176 | 0.040 |
Why?
|
Galactorrhea | 1 | 1999 | 23 | 0.040 |
Why?
|
Lipids | 6 | 2012 | 3343 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 8 | 2016 | 36743 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2013 | 15948 | 0.040 |
Why?
|
Orchiectomy | 1 | 2001 | 466 | 0.040 |
Why?
|
Placebos | 4 | 2008 | 1667 | 0.040 |
Why?
|
Fractures, Bone | 1 | 2011 | 2062 | 0.040 |
Why?
|
Abdomen | 1 | 2004 | 1136 | 0.040 |
Why?
|
Testis | 1 | 2001 | 783 | 0.040 |
Why?
|
Homocysteine | 1 | 2001 | 637 | 0.040 |
Why?
|
Time | 1 | 2019 | 552 | 0.040 |
Why?
|
Animals | 4 | 2020 | 169246 | 0.040 |
Why?
|
Endocrine Glands | 1 | 1997 | 101 | 0.030 |
Why?
|
Fasting | 2 | 2019 | 1610 | 0.030 |
Why?
|
HIV Wasting Syndrome | 1 | 1997 | 99 | 0.030 |
Why?
|
Health Status | 1 | 2010 | 4091 | 0.030 |
Why?
|
Evidence-Based Medicine | 3 | 2015 | 3706 | 0.030 |
Why?
|
Depression | 1 | 2016 | 8230 | 0.030 |
Why?
|
Gonads | 1 | 1996 | 109 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2017 | 13676 | 0.030 |
Why?
|
Medical History Taking | 1 | 1999 | 779 | 0.030 |
Why?
|
Drug Combinations | 1 | 2002 | 2089 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2017 | 506 | 0.030 |
Why?
|
Lipoproteins | 2 | 2012 | 880 | 0.030 |
Why?
|
Metabolic Diseases | 1 | 2002 | 684 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2017 | 9118 | 0.030 |
Why?
|
Oligodendroglioma | 1 | 2017 | 274 | 0.030 |
Why?
|
Glucose | 2 | 2022 | 4352 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2020 | 1363 | 0.030 |
Why?
|
Managed Care Programs | 1 | 2000 | 939 | 0.030 |
Why?
|
Blotting, Southern | 2 | 1992 | 775 | 0.030 |
Why?
|
Regression Analysis | 3 | 2017 | 6340 | 0.030 |
Why?
|
Obesity | 2 | 2014 | 13090 | 0.030 |
Why?
|
Progesterone | 1 | 1999 | 752 | 0.030 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 1992 | 766 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2014 | 162 | 0.030 |
Why?
|
Immune System Diseases | 1 | 2016 | 253 | 0.030 |
Why?
|
Follicle Stimulating Hormone | 3 | 1995 | 727 | 0.030 |
Why?
|
Infertility, Female | 1 | 1999 | 763 | 0.030 |
Why?
|
Gonadotropin-Releasing Hormone | 2 | 1990 | 1149 | 0.030 |
Why?
|
Luteinizing Hormone | 3 | 1995 | 822 | 0.030 |
Why?
|
Ultrasonography | 2 | 2009 | 6004 | 0.030 |
Why?
|
Safety | 1 | 2017 | 1159 | 0.030 |
Why?
|
Cohort Studies | 2 | 2020 | 41754 | 0.030 |
Why?
|
Education | 1 | 2015 | 533 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2016 | 364 | 0.030 |
Why?
|
Diagnostic Imaging | 2 | 2023 | 3533 | 0.030 |
Why?
|
Astrocytoma | 1 | 2017 | 774 | 0.030 |
Why?
|
Glasgow Coma Scale | 1 | 2014 | 574 | 0.020 |
Why?
|
Clone Cells | 2 | 1992 | 1670 | 0.020 |
Why?
|
Massachusetts | 2 | 2012 | 8890 | 0.020 |
Why?
|
Live Birth | 1 | 2015 | 516 | 0.020 |
Why?
|
Osmolar Concentration | 1 | 1992 | 657 | 0.020 |
Why?
|
Survivors | 1 | 2022 | 2381 | 0.020 |
Why?
|
Puberty, Delayed | 1 | 1992 | 124 | 0.020 |
Why?
|
Radiotherapy, Conformal | 1 | 2014 | 549 | 0.020 |
Why?
|
Lipoproteins, LDL | 1 | 2014 | 644 | 0.020 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2015 | 504 | 0.020 |
Why?
|
Liver Function Tests | 1 | 2012 | 526 | 0.020 |
Why?
|
Aging | 3 | 2002 | 8744 | 0.020 |
Why?
|
Aftercare | 1 | 2016 | 916 | 0.020 |
Why?
|
Musculoskeletal Diseases | 1 | 2016 | 599 | 0.020 |
Why?
|
Aminoquinolines | 1 | 1990 | 105 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2015 | 905 | 0.020 |
Why?
|
Urea | 1 | 2012 | 448 | 0.020 |
Why?
|
C-Reactive Protein | 3 | 2010 | 3858 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2661 | 0.020 |
Why?
|
Survival Rate | 2 | 2020 | 12840 | 0.020 |
Why?
|
Visual Fields | 1 | 1996 | 1065 | 0.020 |
Why?
|
Dopamine Agents | 1 | 1990 | 188 | 0.020 |
Why?
|
Cause of Death | 1 | 2020 | 3721 | 0.020 |
Why?
|
Doping in Sports | 1 | 2009 | 62 | 0.020 |
Why?
|
X Chromosome | 1 | 1992 | 819 | 0.020 |
Why?
|
Research | 1 | 1997 | 1979 | 0.020 |
Why?
|
Somatomedins | 1 | 1989 | 179 | 0.020 |
Why?
|
Gallbladder | 1 | 2009 | 308 | 0.020 |
Why?
|
Postoperative Complications | 3 | 2008 | 15832 | 0.020 |
Why?
|
Glucose Intolerance | 1 | 2012 | 579 | 0.020 |
Why?
|
Minerals | 1 | 1989 | 282 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2002 | 416 | 0.020 |
Why?
|
Anthropometry | 2 | 2004 | 1346 | 0.020 |
Why?
|
Growth Hormone-Secreting Pituitary Adenoma | 1 | 2007 | 49 | 0.020 |
Why?
|
Ependymoma | 1 | 2010 | 328 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2014 | 2916 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 1643 | 0.020 |
Why?
|
Calcitriol | 1 | 1989 | 303 | 0.020 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2012 | 465 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2010 | 592 | 0.020 |
Why?
|
Birth Weight | 1 | 2015 | 2121 | 0.020 |
Why?
|
Health Services Research | 1 | 2014 | 1815 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 1997 | 1662 | 0.020 |
Why?
|
Quinolines | 1 | 2012 | 772 | 0.020 |
Why?
|
Gestational Age | 1 | 2015 | 3621 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 4 | 2005 | 20760 | 0.020 |
Why?
|
Cognition | 2 | 2006 | 7073 | 0.020 |
Why?
|
Menstrual Cycle | 3 | 1999 | 546 | 0.020 |
Why?
|
Bone Resorption | 1 | 1989 | 728 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1798 | 0.020 |
Why?
|
Weight Gain | 1 | 2015 | 2359 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12543 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 1997 | 2420 | 0.010 |
Why?
|
Inpatients | 1 | 2016 | 2566 | 0.010 |
Why?
|
Metabolome | 1 | 2011 | 1009 | 0.010 |
Why?
|
Smoking | 1 | 2001 | 9092 | 0.010 |
Why?
|
Psychometrics | 1 | 2014 | 3063 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2012 | 1892 | 0.010 |
Why?
|
Leptin | 1 | 2011 | 1599 | 0.010 |
Why?
|
Infant | 2 | 2018 | 36535 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1992 | 6082 | 0.010 |
Why?
|
Mental Disorders | 2 | 2016 | 6874 | 0.010 |
Why?
|
Clinical Chemistry Tests | 1 | 2003 | 59 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2009 | 1397 | 0.010 |
Why?
|
Self Report | 1 | 2014 | 3773 | 0.010 |
Why?
|
Stress, Physiological | 1 | 1990 | 1408 | 0.010 |
Why?
|
Prevalence | 2 | 2014 | 15869 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2012 | 2029 | 0.010 |
Why?
|
Protons | 1 | 2007 | 1113 | 0.010 |
Why?
|
Glioblastoma | 1 | 2017 | 3464 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2012 | 6029 | 0.010 |
Why?
|
Physical Endurance | 1 | 2004 | 369 | 0.010 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15454 | 0.010 |
Why?
|
Pregnancy Complications | 1 | 2015 | 2973 | 0.010 |
Why?
|
Menopause | 1 | 1989 | 1656 | 0.010 |
Why?
|
Pheochromocytoma | 1 | 2003 | 328 | 0.010 |
Why?
|
Biopsy | 1 | 1992 | 6793 | 0.010 |
Why?
|
Pilot Projects | 1 | 2014 | 8741 | 0.010 |
Why?
|
Inflammation | 1 | 2000 | 10873 | 0.010 |
Why?
|
Pediatrics | 1 | 2015 | 3629 | 0.010 |
Why?
|
Serum Amyloid A Protein | 1 | 2000 | 128 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8748 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6211 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 8054 | 0.010 |
Why?
|
Arousal | 1 | 2006 | 1180 | 0.010 |
Why?
|
Hypogonadism | 1 | 2006 | 805 | 0.010 |
Why?
|
Calcitonin | 1 | 1980 | 328 | 0.010 |
Why?
|
Administration, Intravaginal | 1 | 1999 | 149 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 1999 | 285 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2007 | 1904 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 21538 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 1993 | 5804 | 0.010 |
Why?
|
Primary Ovarian Insufficiency | 1 | 1999 | 108 | 0.010 |
Why?
|
Weight Loss | 1 | 1990 | 2721 | 0.010 |
Why?
|
Thyroid Hormones | 1 | 2001 | 407 | 0.010 |
Why?
|
Child Development | 1 | 2010 | 2330 | 0.010 |
Why?
|
Affect | 1 | 2006 | 1495 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 2001 | 529 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2003 | 1622 | 0.010 |
Why?
|
Kinetics | 2 | 2002 | 6329 | 0.010 |
Why?
|
Nutrition Assessment | 1 | 2001 | 740 | 0.010 |
Why?
|
Gels | 1 | 1999 | 423 | 0.010 |
Why?
|
Reoperation | 1 | 2008 | 4329 | 0.010 |
Why?
|
Emotions | 1 | 2009 | 2767 | 0.010 |
Why?
|
Carrier Proteins | 2 | 2002 | 4937 | 0.010 |
Why?
|
Echocardiography | 1 | 2009 | 5047 | 0.010 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 1997 | 241 | 0.010 |
Why?
|
Endometrium | 1 | 1999 | 406 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2006 | 2197 | 0.010 |
Why?
|
Insulin-Like Growth Factor Binding Protein 2 | 1 | 1996 | 69 | 0.010 |
Why?
|
Muscle, Skeletal | 2 | 2004 | 4978 | 0.010 |
Why?
|
Glycoproteins | 1 | 2002 | 2202 | 0.010 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 1997 | 553 | 0.010 |
Why?
|
Folic Acid | 1 | 2001 | 1337 | 0.010 |
Why?
|
Seizures | 1 | 1987 | 2998 | 0.010 |
Why?
|
Morbidity | 1 | 1998 | 1755 | 0.010 |
Why?
|
Statistics as Topic | 1 | 1999 | 2357 | 0.010 |
Why?
|
Ion Exchange | 1 | 1972 | 16 | 0.010 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1993 | 284 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2009 | 10399 | 0.010 |
Why?
|
Muscles | 1 | 1997 | 1582 | 0.010 |
Why?
|
Risk Assessment | 1 | 2013 | 24315 | 0.010 |
Why?
|
Amphetamine | 1 | 1972 | 222 | 0.010 |
Why?
|
Phosphoglycerate Kinase | 1 | 1990 | 66 | 0.010 |
Why?
|
Hypoxanthine Phosphoribosyltransferase | 1 | 1990 | 69 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2000 | 3228 | 0.010 |
Why?
|
Narcotics | 1 | 1972 | 332 | 0.010 |
Why?
|
Libido | 1 | 1990 | 124 | 0.010 |
Why?
|
Energy Intake | 1 | 1997 | 2146 | 0.010 |
Why?
|
Dosage Compensation, Genetic | 1 | 1990 | 209 | 0.010 |
Why?
|
Carcinoma | 1 | 1980 | 2332 | 0.000 |
Why?
|
Disabled Persons | 1 | 1998 | 1210 | 0.000 |
Why?
|
Nutritional Status | 1 | 1997 | 1628 | 0.000 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 12252 | 0.000 |
Why?
|
Methylation | 1 | 1990 | 1078 | 0.000 |
Why?
|
Thyroid Neoplasms | 1 | 1980 | 2360 | 0.000 |
Why?
|
Erectile Dysfunction | 1 | 1990 | 437 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1998 | 8542 | 0.000 |
Why?
|
Menarche | 1 | 1989 | 538 | 0.000 |
Why?
|
Energy Metabolism | 1 | 1997 | 2907 | 0.000 |
Why?
|
Hypnotics and Sedatives | 1 | 1972 | 1191 | 0.000 |
Why?
|
Chronic Disease | 1 | 1998 | 9384 | 0.000 |
Why?
|
Pentagastrin | 1 | 1980 | 17 | 0.000 |
Why?
|
Neoplasms | 1 | 2010 | 22371 | 0.000 |
Why?
|
Exercise | 1 | 1996 | 5955 | 0.000 |
Why?
|
Substance-Related Disorders | 1 | 1972 | 4423 | 0.000 |
Why?
|
Chromatography, Thin Layer | 1 | 1972 | 212 | 0.000 |
Why?
|
Methods | 1 | 1972 | 1066 | 0.000 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1972 | 2486 | 0.000 |
Why?
|